Navigation Links
Newfound roadblock to interferon effectiveness against malignant melanoma

Researchers have uncovered a significant contributing factor to interferon resistance of malignant melanoma cells. The finding represents a step forward in understanding the molecular events that govern the growth of this type of cancer and the changes in gene expression and cellular signaling that underlie resistance to established therapies.

Malignant melanoma is the deadliest form of skin cancer, and if not treated successfully, it can spread to affect the liver, lungs, or brain. Chemotherapy fights the disease with limited efficiency, and the use of interferon has become the most established immunotherapy for advanced-stage melanoma. However, melanoma tumors often develop a resistance to the drug, posing one of the major obstacles in the clinical treatment of this cancer.

Now Professor Manfred Schartl and Dr. Claudia Wellbrock, scientists at the University of W�rzburg, believe they have an explanation for how this interferon resistance is acquired. They have found that when a gene called STAT5 is too active in melanoma cells, it can counteract the anti-cancer effect of interferon. Interferon normally impedes the growth of cancer cells, whereas STAT5 is thought to act to promote cellular growth.

The new work, published by Professor Schartl and his colleagues in Current Biology, shows that interferon actually activates STAT5 in melanoma cells but that under normal conditions, this does not interfere with the inhibitory potential of the drug. However, when cancer cells posses too much STAT5 activity to begin with, the further activation of STAT5 function by interferon induces a mechanism that blocks the ability of the drug to effectively inhibit growth.

Confirming this initial finding, the researchers found that when they inhibited STAT5 in interferon-resistant melanoma cells, they were able to restore the effectiveness of interferon. This demonstrates the relevance of STAT5 and its contribution to the behavior of melanoma cells in th e late stage of the disease.

The findings explain the frequent failure of interferon therapies and thus further our understanding of melanoma in its late, and most aggressive, stage. In the future, a routine analysis of the STAT5 status in melanoma patients might help to improve and personalize therapies.


'"/>

Source:Cell Press


Related biology news :

1. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
2. Greasing interferons gears may pave way to greater therapeutic benefits, fewer side effects
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Man-made wetlands effectiveness similar to natural marsh
5. UCLA study assesses cost-effectiveness of Hepatitis B drugs
6. Structures of marine toxins provide insight into their effectiveness as cancer drugs
7. Test reveals effectiveness of potential Huntingtons disease drugs
8. Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness
9. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
10. Bound for destruction: Ubiquitination protects against improper Notch signaling
11. Female sex hormones play a vital role in defense against sexually transmitted diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:5/16/2017)... TEANECK, N.J. , May 16, 2017  Veratad ... leading provider of online age and identity verification solutions, ... the K(NO)W Identity Conference 2017, May 15 thru May ... Ronald Regan Building and International Trade Center. ... across the globe and in today,s quickly evolving digital ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
Breaking Biology News(10 mins):
(Date:7/25/2017)... ... July 25, 2017 , ... Fiberstar, Inc ., a global market ... Citri-Fi® 125. This natural citrus fiber is used to improve tomato-based food products by ... sauces, condiments and spreads. Today, more than ever, consumers connect ingredients to the foods ...
(Date:7/24/2017)... ... ... Charm Sciences, Inc. is pleased to announce the Charm® ROSA® Tetracycline-SL (Dilution ... (NCIMS) Laboratory Committee and Appendix N Committee as a drug residue test kit for ... voted at its annual meeting in April, 2015 to establish a pilot program to ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... the stock market news outlet had initiated coverage on Interpace Diagnostics. Interpace ... and identifies exposure, progression and risk analysis from specific cancers in humans. ...
(Date:7/20/2017)... ... 20, 2017 , ... Dr. Asher Kimchi, Founder and Chairman of the ... Awards at the 22nd World Congress on Heart Disease held in Vancouver, BC, Canada. ... the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Co-Chairmen Dr. John A. ...
Breaking Biology Technology: